Emicizumab

Pharmacokinetics

Pharmacokinetics

• Rout of administration: Exclusively subcutaneous injection.
• Bioavailability (F): Approximately 80% after peripheral subcutaneous administration. Slow absorption that reaches stable therapeutic plateau in about 4 to 6 weeks after initial induction loading doses.
• Distribution: Small apparent volume of distribution (approx. 9 L), compatible with intravascular distribution of monoclonal IgG antibodies.
• Metabolism and Excretion: Nonspecific cellular catabolism to free amino acids mediated by the reticuloendothelial system and lysosomal internalization. It does not undergo direct renal excretion or microsomal hepatic clearance.
• Half-life (t_1/2): Extremely long, approximately 4 to 5 weeks (28 to 30 days), enabling widely spaced injection regimens (once a week, every 2 weeks or every 4 weeks).

Indicators and dose

Indications

• Systematic prophylaxis of bleeding episodes in patients of all ages with congenital Hemophilia A (Factor VIII deficiency) with demonstrated presence of inhibitory antibodies against Factor VIII.
• Prophylaxis in patients with severe Hemophilia A without the presence of anti-Factor VIII inhibitory antibodies, reducing the injectable frequency of traditional prophylactic replacement therapies.

Dosage and Schemes

• Loading dose (Induction): 3.0 mg/kg subcutaneously once a week for the first 4 consecutive weeks.
• Maintenance dose: Adjusted to the patient's convenience according to the following equivalent guidelines:
  - 1.5 mg/kg subcutaneously once a week.
  - 3.0 mg/kg subcutaneously once every 2 weeks.
  - 6.0 mg/kg subcutaneously once every 4 weeks (monthly).

Pregnancy and Breastfeeding

FDA Category C. IgG4 class monoclonal antibodies actively cross the placenta from the second trimester of gestation. Its administration is not recommended during pregnancy due to the theoretical risk of inducing abnormal thrombotic phenomena in utero or rebound hemorrhages after birth in the newborn.

Security

Contraindications

• Known hypersensitivity to emicizumab or excipients of the preparation.
• Simultaneous coadministration with hemostatic bypass agents (especially Activated Prothrombin Complex Concentrate - aPCC/FEIBA) without strict supervision, due to the risk of serious microangiopathic complications.

Adverse Effects (ADR)

Critical Safety Alert: Thrombotic Microangiopathy and Sinusoidal Thrombosis

In phase III clinical trials, the concomitant administration of prophylactic emicizumab with high cumulative doses of Activated Prothrombin Complex Concentrate (aPCC/FEIBA > 100 U/kg/24 hours) for a period greater than 24 hours for the treatment of breakthrough bleeding, was directly associated with the development of Thrombotic Microangiopathy (TMA) and thrombosis of cerebral venous sinuses or skin necrosis. This is secondary to the extreme synergistic stimulation of thrombin generation produced by the conjunction of emicizumab with the activated factors of the prothrombin complex. If a patient treated with emicizumab requires a bypass agent, the use of recombinant activated Factor VIIa (rFVIIa/Novoseven) should be preferred and the use of aPCC should be absolutely restricted.

• Local reactions at the injection site: Mild erythema, pruritus, pain and edema.
• Transient headache and insomnia.
• Mild myalgias and arthralgias.

Interactions

Significantly alters laboratory determinations of hemostasis. The presence of emicizumab in plasma artificially normalizes or shortens activated Partial Thromboplastin Time (aPTT)and aPTT-based factor VIII assays, rendering these classic analytical tests useless. To monitor hemostatic activity in patients treated with emicizumab, Factor VIII chromogenic assays based on reagents of bovine origin (which are not influenced by the action of emicizumab) must be used.